278 related articles for article (PubMed ID: 8422000)
1. Spironolactone in congestive heart failure refractory to high-dose loop diuretic and low-dose angiotensin-converting enzyme inhibitor.
van Vliet AA; Donker AJ; Nauta JJ; Verheugt FW
Am J Cardiol; 1993 Jan; 71(3):21A-28A. PubMed ID: 8422000
[TBL] [Abstract][Full Text] [Related]
2. Effectiveness of spironolactone added to an angiotensin-converting enzyme inhibitor and a loop diuretic for severe chronic congestive heart failure (the Randomized Aldactone Evaluation Study [RALES]).
Am J Cardiol; 1996 Oct; 78(8):902-7. PubMed ID: 8888663
[TBL] [Abstract][Full Text] [Related]
3. Effects of spironolactone on exercise capacity and neurohormonal factors in patients with heart failure treated with loop diuretics and angiotensin-converting enzyme inhibitor.
Kinugawa T; Ogino K; Kato M; Furuse Y; Shimoyama M; Mori M; Endo A; Kato T; Omodani H; Osaki S; Miyakoda H; Hisatome I; Shigemasa C
Gen Pharmacol; 1998 Jul; 31(1):93-9. PubMed ID: 9595286
[TBL] [Abstract][Full Text] [Related]
4. ACE inhibitor co-therapy in patients with heart failure: rationale for the Randomized Aldactone Evaluation Study (RALES).
Pitt D
Eur Heart J; 1995 Dec; 16 Suppl N():107-10. PubMed ID: 8682055
[TBL] [Abstract][Full Text] [Related]
5. Angiotensin-converting enzyme inhibitor and spironolactone combination therapy. New objectives in congestive heart failure treatment.
Zannad F
Am J Cardiol; 1993 Jan; 71(3):34A-39A. PubMed ID: 8422003
[TBL] [Abstract][Full Text] [Related]
6. Captopril and spironolactone therapy for refractory congestive heart failure.
Dahlström U; Karlsson E
Am J Cardiol; 1993 Jan; 71(3):29A-33A. PubMed ID: 8422001
[TBL] [Abstract][Full Text] [Related]
7. Effects of adding spironolactone to an angiotensin-converting enzyme inhibitor in chronic congestive heart failure secondary to coronary artery disease.
Barr CS; Lang CC; Hanson J; Arnott M; Kennedy N; Struthers AD
Am J Cardiol; 1995 Dec; 76(17):1259-65. PubMed ID: 7503007
[TBL] [Abstract][Full Text] [Related]
8. Determinants of increased angiotensin II levels in severe chronic heart failure patients despite ACE inhibition.
van de Wal RM; Plokker HW; Lok DJ; Boomsma F; van der Horst FA; van Veldhuisen DJ; van Gilst WH; Voors AA
Int J Cardiol; 2006 Jan; 106(3):367-72. PubMed ID: 16337046
[TBL] [Abstract][Full Text] [Related]
9. Is there a role for renin profiling in selecting chronic heart failure patients for ACE inhibitor treatment?
Lim PO; MacFadyen RJ; Struthers AD
Heart; 2000 Mar; 83(3):257-61. PubMed ID: 10677399
[TBL] [Abstract][Full Text] [Related]
10. Striking increase of natriuresis by low-dose spironolactone in congestive heart failure only in combination with ACE inhibition: mechanistic evidence to support RALES.
Bauersachs J; Fraccarollo D; Ertl G; Gretz N; Wehling M; Christ M
Circulation; 2000 Nov; 102(19):2325-8. PubMed ID: 11067783
[TBL] [Abstract][Full Text] [Related]
11. [Diuretic therapy in congestive heart failure--new views on spironolactone therapy].
Haller C
Ther Umsch; 2000 Jun; 57(6):374-9. PubMed ID: 10894022
[TBL] [Abstract][Full Text] [Related]
12. Effect of renin-angiotensin-aldosterone system triple blockade on non-diabetic renal disease: addition of an aldosterone blocker, spironolactone, to combination treatment with an angiotensin-converting enzyme inhibitor and angiotensin II receptor blocker.
Furumatsu Y; Nagasawa Y; Tomida K; Mikami S; Kaneko T; Okada N; Tsubakihara Y; Imai E; Shoji T
Hypertens Res; 2008 Jan; 31(1):59-67. PubMed ID: 18360019
[TBL] [Abstract][Full Text] [Related]
13. Angiotensin II receptor antagonists and heart failure: angiotensin-converting-enzyme inhibitors remain the first-line option.
Prescrire Int; 2005 Oct; 14(79):180-6. PubMed ID: 16285075
[TBL] [Abstract][Full Text] [Related]
14. [Classic treatment of chronic heart insufficiency. What if new?].
Aumont MC; Agnola D; Juliard JM; Karrillon G
Arch Mal Coeur Vaiss; 1995 Apr; 88(4 Suppl):599-602. PubMed ID: 7487308
[TBL] [Abstract][Full Text] [Related]
15. Renal effects of angiotensin-converting enzyme inhibition in cardiac failure.
Dzau VJ
Am J Kidney Dis; 1987 Jul; 10(1 Suppl 1):74-80. PubMed ID: 3037893
[TBL] [Abstract][Full Text] [Related]
16. Spironolactone improves cardiac sympathetic nerve activity and symptoms in patients with congestive heart failure.
Kasama S; Toyama T; Kumakura H; Takayama Y; Ichikawa S; Suzuki T; Kurabayashi M
J Nucl Med; 2002 Oct; 43(10):1279-85. PubMed ID: 12368364
[TBL] [Abstract][Full Text] [Related]
17. Aldosterone antagonism in addition to angiotensin-converting enzyme inhibitors in heart failure.
Bauersachs J; Fraccarollo D
Minerva Cardioangiol; 2003 Apr; 51(2):155-64. PubMed ID: 12783071
[TBL] [Abstract][Full Text] [Related]
18. [Anti-aldosterone therapy in severe heart failure].
van Guldener C; Donker AJ
Ned Tijdschr Geneeskd; 1999 Aug; 143(34):1724-6. PubMed ID: 10494316
[TBL] [Abstract][Full Text] [Related]
19. [Value of aldosterone receptor blockade in diuretic therapy of patients with chronic heart failure].
Christ M; Ludwig N; Maisch B
Herz; 2002 Mar; 27(2):135-49. PubMed ID: 12025459
[TBL] [Abstract][Full Text] [Related]
20. How prevalent is hyperkalemia and renal dysfunction during treatment with spironolactone in patients with congestive heart failure?
Svensson M; Gustafsson F; Galatius S; Hildebrandt PR; Atar D
J Card Fail; 2004 Aug; 10(4):297-303. PubMed ID: 15309695
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
